Dashboard Tools Market News Investing Ideas Pricing About Us
Sign Up
Log in
C

Celadon Pharmaceuticals PLC
LSE:CEL

Watchlist Manager
Celadon Pharmaceuticals PLC
LSE:CEL
Watchlist
Price: 13.4 GBX
Market Cap: £9.2m
Write Note Create Alert Ask AI
Financials Section:
Income Statement Balance Sheet Cash Flow Statement

Balance Sheet

Assets
+
3Y
+12 248%
5Y
-
10Y
-
Liabilities
+
3Y
+5 900%
5Y
-
10Y
-
Equity
+
3Y
+15 277%
5Y
-
10Y
-

Balance Sheet Decomposition
Celadon Pharmaceuticals PLC

Balance Sheet
Celadon Pharmaceuticals PLC

Rotate your device to view
Balance Sheet
Currency: GBP
Dec-2021 Dec-2022 Dec-2023 Dec-2024
Assets
Cash & Cash Equivalents
4
5
1
298
Cash
0
0
0
298
Cash Equivalents
4
5
1
0
Short-Term Investments
0
1 603
1 304
1 606
Total Receivables
0
0
200
25
Accounts Receivables
0
0
200
25
Other Receivables
0
0
0
0
Inventory
0
0
0
0
Other Current Assets
0
38
14
8
Total Current Assets
4
1 853
1 908
1 937
PP&E Net
3
321
306
278
PP&E Gross
3
321
306
278
Accumulated Depreciation
0
34
53
72
Intangible Assets
0
0
0
0
Goodwill
1
0
0
0
Long-Term Investments
0
53
2
0
Other Long-Term Assets
0
16
14
27
Other Assets
1
0
0
0
Total Assets
9
N/A
2 243
+25 500%
2 230
-1%
2 242
+1%
Liabilities
Accounts Payable
1
29
39
15
Accrued Liabilities
0
94
61
58
Short-Term Debt
0
0
0
0
Current Portion of Long-Term Debt
7
0
0
0
Other Current Liabilities
0
0
10
15
Total Current Liabilities
9
121
109
88
Long-Term Debt
4
0
0
0
Deferred Income Tax
0
0
0
0
Minority Interest
0
1
0
0
Other Liabilities
0
246
238
222
Total Liabilities
13
N/A
368
+2 749%
347
-6%
310
-11%
Equity
Common Stock
0
2
2
3
Retained Earnings
12
846
1 000
1 366
Additional Paid In Capital
7
2 735
2 878
3 294
Treasury Stock
0
0
0
0
Other Equity
0
16
2
2
Total Equity
4
N/A
1 875
N/A
1 883
+0%
1 932
+3%
Total Liabilities & Equity
9
N/A
2 243
+25 500%
2 230
-1%
2 242
+1%
Shares Outstanding
Common Shares Outstanding
8
79
80
86

See Also

Summary
CEL intrinsic value, competitors valuation, and company profile.
DCF Valuation
CEL stock valuation using Discount Cash Flow valuation method.
Relative Valuation
CEL stock valuation using valuation multiples.
Wall Street Estimates
CEL price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
CEL stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Follow us
Join more than 314,800+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.